Erbitux Gets C-Code Reimbursement; Waits For Green Light On J-Code
This article was originally published in The Pink Sheet Daily
ImClone has not seen "obstacles" to reimbursement across all patients. During the quarter, Erbitux generated $17.5 mil. in sales.
You may also be interested in...
The colorectal cancer therapy will be available to patients Feb. 25. Bristol will use its Oncology Therapeutic Network subsidiary as Erbitux' single-source distributor.
“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.
QLT now has worldwide marketing rights to the topical acne treatment. Astellas believes labeling proposed by FDA will limit the market profile for Aczone, the company said. Aczone’s user fee deadline is July 7.